ALK Inhibitor Shows Promise in Rare, Progressive Tumor Types

Published Date: 24 Jun 2024

Phase II study found brigatinib exceeded historical control by shrinking 10% of targeted tumors

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Genetics and therapy type determine second cancer risk after childhood treatment, study finds

2.

Retifanlimab-Chemo Combo Boosts PFS in Advanced Squamous Cell Anal Cancer

3.

ASCO: Durvalumab plus FLOT beneficial for resectable gastric, GE junction cancer

4.

Alternative Medicine for Breast Cancer: Study Raises Concern

5.

ALK Inhibitor Shows Promise in Rare, Progressive Tumor Types


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot